Table of Contents Table of Contents
Previous Page  110 / 112 Next Page
Information
Show Menu
Previous Page 110 / 112 Next Page
Page Background

108

NCCN Guidelines for Patients

®

Prostate Cancer, Version 1.2016

Index

Index

active surveillance

14, 24, 30, 48–51, 54–55, 64

androgen deprivation therapy

36–37, 39–40, 42, 48,

50, 52–54, 56–64, 67–68, 70–74, 78–80, 88

biopsy

15–16, 18, 20, 24, 27, 46, 48–51, 61, 70, 72–73

bone scan

25–27, 70–73

brachytherapy

37–38, 48–51, 54, 58–61, 72–73

chemotherapy

40–42, 44, 81–84, 86–88

clinical trial

43–44, 81, 84–85, 87–88

computed tomography

25–27, 70–73

cryosurgery

38, 43–44, 72

digital rectal exam

13, 15, 18, 20, 48–51, 54, 69–71, 73,

79–80, 83

external beam radiation therapy

36–38, 48–54, 56–64,

70, 83

fine-needle aspiration

27–28

Gleason score

16–17, 20, 24–25, 46, 49, 51, 61, 70, 73

hormone therapy

39–41, 44, 66, 68, 76, 79–88

immunotherapy

40–41, 44, 82–83

life expectancy

22–23, 25, 28

magnetic resonance imaging

14–16, 25–27, 48–51, 55,

70–73

molecular testing

24, 55

NCCN Member Institutions

107

NCCN Panel Members

106

nomogram

24–25, 28, 34, 49, 51, 55, 97

observation

48, 50, 52–54, 56–61, 70–73, 78–81, 88

pelvic lymph node dissection

34, 44, 48–51, 54–55,

58–61, 72–73

prostatectomy

31–35, 43–44, 48–61, 66, 70, 72–73

prostate-specific antigen

12–13, 15, 18, 20, 23–25, 30,

40, 46, 48–51, 53–55, 57, 59, 61, 63, 69–73, 79, 81, 83

radiopharmaceuticals

42, 44, 83

stereotactic body radiotherapy

37